Leaving UCSF, Desmond-Hellman Will Become Gates Foundation CEO
This article was originally published in The Pink Sheet Daily
Ex-Genentech executive Susan Desmond-Hellman soon will leave her position as UCSF chancellor to become CEO of the Gates Foundation. Her move signals the foundation’s ambition to lead in the science and the financing of neglected and tropical diseases, as well as in the global alliances that enable both.
You may also be interested in...
Vaccine consultant Jacqueline Keith in an interview described promising advances but also challenges to the funding, development, and delivery of vaccines to the neediest populations. The role of public/private partnerships at each stage of the vaccine value chain is critical to assuring win-win outcomes.
Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.
At Bio-Windhover's Pharmaceutical Strategic Outlook conference, Susan Desmond-Hellmann discussed UCSF's evolving relationships with big pharma.